Tag: BP11

CuraTeQ

CuraTeQ Biologics’ successful phase 1 trial of BP11

HTP Desk - 0
CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, announced that their Omalizumab biosimilar candidate BP11 has met the Phase 1 trial endpoints vis-à-vis the EU...